Back to News
Dec 11, 2025 12:00 PM

Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain

Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the Phase 3 TRIUMPH-4 trial evaluating the two highest investigational doses of retatrutide.

Eli Lilly shares are advancing steadily. Why is LLY stock trading higher?

Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes.

Each dose of retatrutide (9 mg and 12 mg) met all primary and key secondary endpoints, delivering significant weight loss and improvements in pain and physical function at 68 weeks using both the efficacy and treatment-regimen estimands.

Also Read: Zepbound Just Got Cheaper: Lilly Cuts Prices On LillyDirect ...